New therapies help people with schizophrenia, but access is woefully inadequate

Schizophrenia, recognized by experts since 1899, is among the top 10 leading causes of disability worldwide. This disorder, once classified under "dementia praecox," manifests through hallucinations, irrational beliefs, and a progressive decline in daily functioning. Despite Kraepelin's incorrect belief in its inevitable worsening, studies show that around 40% of individuals with schizophrenia maintain mild or no symptoms and lead functional lives. However, for the majority, schizophrenia poses persistent challenges, often leading to isolation.

In the U.S., schizophrenia ranks among the top 10 causes of disability, with an estimated 1 in 5 homeless individuals affected. Moreover, 15% of U.S. state prison inmates suffer from severe mental illnesses like schizophrenia. These public health concerns highlight the urgent need for effective treatments.

Cognitive and social difficulties, previously overlooked, form the core of schizophrenia. People with the disorder often struggle with attention, retaining information, and forming new memories. In everyday situations, these cognitive impairments can go unnoticed, making it challenging to provide proper support.

Emerging therapies are offering hope to those affected. Cognitive remediation, a new treatment, employs exercises designed to enhance mental sharpness, such as remembering the location of items in a refrigerator to improve supermarket navigation. Other therapies focus on teaching social skills, like interpreting emotions and motivations, to help people with schizophrenia navigate social interactions.

Over the past 15 years, these innovative therapies have demonstrated efficacy in clinical trials, improving cognition and daily functioning.